Cargando…

Retraction of “Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)”

Detalles Bibliográficos
Autores principales:	Nalawansha, Dhanusha A., Paiva, Stacey-Lynn, Rafizadeh, Diane N., Pettersson, Mariell, Qin, Liena, Crews, Craig M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2020
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047427/ https://www.ncbi.nlm.nih.gov/pubmed/32123750 http://dx.doi.org/10.1021/acscentsci.0c00021

Ejemplares similares

Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs)
por: Nalawansha, Dhanusha A., et al.
Publicado: (2019)

Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)

Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19
por: Nalawansha, Dhanusha A., et al.
Publicado: (2020)

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
por: Lebraud, Honorine, et al.
Publicado: (2016)

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
por: Yamanaka, Satoshi, et al.
Publicado: (2023)

Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance
por: Salami, Jemilat, et al.
Publicado: (2018)

Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins
por: Pance, Katarina, et al.
Publicado: (2022)

Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
por: Kim, Kidae, et al.
Publicado: (2019)

Mutagenesis Studies of the 14 Å Internal Cavity of Histone Deacetylase 1: Insights toward the Acetate-Escape Hypothesis and Selective Inhibitor Design
por: Wambua, Magdalene K., et al.
Publicado: (2014)

Key Considerations in Targeted Protein Degradation Drug Discovery and Development
por: Qin, Liena, et al.
Publicado: (2022)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

DNA framework-engineered chimeras platform enables selectively targeted protein degradation
por: Zhou, Li, et al.
Publicado: (2023)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
por: Chen, Jin‐Jiao, et al.
Publicado: (2023)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
por: Alabi, Shanique B., et al.
Publicado: (2021)

Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders
por: Haniff, Hafeez S., et al.
Publicado: (2020)

Assembly and targeting of adaptin chimeras in transfected cells
Publicado: (1993)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Shining a Light on Proteolysis Targeting Chimeras
por: Teichmann, Ellen, et al.
Publicado: (2019)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021)

The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)

Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1
por: Hu, Mingxing, et al.
Publicado: (2020)

Synthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenase
por: Sohbati, Hamidreza, et al.
Publicado: (2022)

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
por: Tseng, Yu-Ling, et al.
Publicado: (2023)

Targeting of an Intestinal Apical Endosomal Protein to Endosomes in Nonpolarized Cells
por: Wilson, Jean M., et al.
Publicado: (1997)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
por: Manda, Sudhakar, et al.
Publicado: (2020)

A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth
por: Li, Xin, et al.
Publicado: (2022)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
por: Fiskus, Warren, et al.
Publicado: (2021)

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines
por: Chan, Karina, et al.
Publicado: (2023)

Design, Synthesis, and Antitumor Activity Evaluation of Proteolysis-Targeting Chimeras as Degraders of Extracellular Signal-Regulated Kinases 1/2
por: Pan, Pengming, et al.
Publicado: (2023)

Endosomal LC3C-pathway selectively targets plasma membrane cargo for autophagic degradation
por: Coelho, Paula P., et al.
Publicado: (2022)

Tissue Targeted Embryonic Chimeras: Zebrafish Gastrula Cell Transplantation
por: Deschene, Elizabeth R., et al.
Publicado: (2009)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6vb0viqe2bjfe2q14c0kecl1ht